Calistoga Pharmaceuticals, Inc.

Calistoga Pharmaceuticals, Inc. focuses on developing innovative therapies for cancer treatment, leveraging cutting-edge technology to advance their medical solutions. Founded in 2006 and headquartered in Seattle, US, Calistoga Pharmaceuticals, Inc. specializes in targeted cancer therapies.

In February 2011, Gilead Sciences, Inc. acquired Calistoga for USD 375 mn. The company has participated in 7 deals, with the most recent one occurring on February 22, 2011, during which it raised a total of USD 375 mn. Calistoga Pharmaceuticals, Inc.

is dedicated to developing targeted therapies for cancer treatment, utilizing novel small molecule inhibitors to address specific cancer pathways. The company is recognized for its pioneering research aimed at enhancing the efficacy of cancer treatments through innovative drug development. Calistoga Pharmaceuticals, Inc. 's revenue stems from its focused approach to drug development, culminating in its acquisition by Gilead Sciences, Inc.

for USD 375 mn. The financial framework aligns with the company’s growth and operational strategies. With the acquisition by Gilead Sciences, Inc. , Calistoga Pharmaceuticals, Inc.

is positioned for considerable growth in the oncology sector. The recent funding will support the continued development of targeted cancer therapies and the exploration of new drug formulations to meet emerging market demands.